Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.

Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.

The regulatory agency gave a PDUFA target action date of April 6, 2026, for Orca-T among patients with AML, ALL, and MDS.

Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.

Data support the intravesical mitomycin solution’s role as an innovative option for those with recurrent, low-grade, intermediate-risk NMIBC.

The safety profile of dato-DXd was consistent with previous clinical trials assessing the agent in breast cancer.

Casdatifan, administered at 100 mg once daily, achieved a confirmed ORR of 35% in patients with pretreated metastatic kidney cancer.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

RLT-based combinations, RLTs across genitourinary cancers, and RLTs in earlier lines of therapy are among the considerations for further research.

A study by the Blood and Marrow Transplant Clinical Trials Network found that a donor search prognosis strategy may move those with cancer to HCT faster.

Grade 2 or higher genitourinary acute toxicity was observed in 27.3% of patients treated with 2 fractions of SBRT vs 29.2% of patients treated with 5 fractions.

Those with limited-stage small cell lung cancer who had elevated ProGRP levels at baseline had worse OS and PFS outcomes vs those with normalized levels.

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.

Treatment-related AEs with sunvozertinib were consistent with EGFR tyrosine kinase inhibitors in patients with NSCLC with EGFR exon 20 insertion mutations.

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.

The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.

Combination therapy of ETX-636 plus fulvestrant is being administered to patients with HR–positive, HER2-negative breast cancer in a phase 1/2 trial.

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

In the phase 3 EMBER-3 trial, Guardant360 CDx was used to identify patients with ESR1-mutated advanced breast cancer who may benefit from imlunestrant.

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.